Bayer AG stock (DE000BAY0017): Xetra weakness after a mixed session

Bayer AG shares were last reported down 2.3% to EUR 35.68 in Xetra trading on 06/02/2026, according to a market update shared in the latest Bayer-related video clip and broader DAX commentary. The move keeps the stock anchored in Germany's listed large-cap universe, where Frankfurt trading remains the main reference point for local investors and the company's home-country market narrative.

The same update also referenced a broader EUR 166.92 market level in the surrounding discussion, underscoring how quickly sentiment can shift in Bayer-linked trading commentary. No completed delisting or take-private transaction has been evidenced in the dated allowed-source material reviewed for this article, so the shares continue to be treated as actively listed on the home market.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

Bayer AG: core business model

Bayer combines prescription medicines, over-the-counter health products and agricultural inputs in a diversified operating model that still centers on its German listing and home-market reporting rhythm.

Latest quarterly results for Bayer AG at a glance

Bayer's most recently verified quarterly disclosure remains the first-quarter 2026 report published on 05/14/2026, which is the latest formal earnings reference available for Tuesday's module. In that release, the company said crop science, pharmaceuticals and consumer health all remained part of the reporting mix, keeping investors focused on margin recovery, litigation exposure and cash generation rather than a single-line growth story.

The quarter mattered for the German market because Bayer is still a DAX-name with a strong domestic following, and Frankfurt traders tend to react quickly to any hint of progress or pressure in the company's operating segments. That keeps the stock closely tied to home-country earnings season even when the immediate catalyst is a market-price move rather than a fresh filing.

Conclusion

The latest Xetra move keeps Bayer in focus as a German-listed large cap, while Tuesday's earnings module points investors back to the 05/14/2026 quarterly release for the next fundamental reference. Until a fresh company filing or analyst update changes the picture, the stock's day-to-day tone is likely to remain tied to Frankfurt trading and segment-level execution.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.